Malignant lymphoma arising from natural killer cells: Report of the first case in 1970 and newer developments in the FasL→FasR system

Acta Microbiologica et Immunologica Hungarica

Volumn 44, Issue 3, 1997, Pages 295-307

  Sinkovics, J G ^a,b,c  

^a ST JOSEPH HOSPITAL   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN;

ARTICLE; CASE REPORT; HUMAN; IMMUNOLOGY; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; NATURAL KILLER CELL; PATHOLOGY;

ANTIGENS, CD95; FAS LIGAND PROTEIN; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOMA; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED;

EID: 0031297489     PISSN: 12178950     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Lee, R.K., Spielman, J., Zhao, D.Y., Olsen, K.Y., Podack, E.R.: Perforin, Fas ligand and tumour necrosis factor are the major cytotoxic molecules used by lymphokine activated killer cells. J Immunol 157, 1919 (1996).
2. + T cells via Fas/Fas ligand-mediated apoptosis. J Immunol 158, 1503 (1997).
3. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., Ferguson, TA.: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 27, 1189 (1995).
4. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., Duke, RC.: A role for CD95 ligand in preventing graft rejection. Nature 377, 630 (1995).
5. Stuart, P.M., Griffith, T.S., Usui, N., Pepose, J., Yu, X., Ferguson, T.A.: CD95 ligand (Fas-) induced apoptosis is necessary for corneal allograft. J Clin Investig 99, 396 (1997).
6. Baker, M.B., Riley, R.L., Podack, E.R., Levy, R.B.: Graft-versus-host disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function but not perform function. Proc Nat Acad Sci USA 94, 1366 (1997).
7. Via, C.S., Nguyen, P., Shustor, A., Drappa, J., Elkon, K.B.: A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157, 5387 (1996).
8. Uckan, D., Steele, A., Good, R.A.: The FasL→FasR system in pregnancy, graft-vs-host reaction and transplantation and tumour immunology. Manuscript in print 1996-7 (personal communications).
9. Tanaka, M., Suda, T., Haze, K., Nakamura, N., Soto, K., Kimura, F., Motoyoshi, K., Mizuki, H., Tagawa, S., Ohga, S., Hatake, K., Drummond, A.H., Nagata, J.: Fas ligand in human serum. Nature Med 2, 317 (1996).
10. Shullenberger, C.C., Sinkovics, J.G.: Lymphocytic cytotoxins in wasting syndrome. New Engl J Med 283, 1350 (1970).
11. Sinkovics, J.G., Shullenberger, C.C.: "Cytotoxic lymphoma": do neoplastic lymphoid cells produce cytotoxins in vivo? First Meeting European Division International Society Haematology Sept. 10 1971. Milan Italy Abstract #273.
12. Sinkovics, J.G., Dreyer, D.A., Shirato, E., Cabiness, J.R., Shullenberger, C.C.: Cytotoxic lymphocytes. I. Destruction of neoplastic cells by lymphocytes in cultures of human origin. Texas Rep Biol Med 29, 228 (1971).
13. Sinkovics, J.G., Gyorkey, F., Kusyk, C., Siciliano, M.J.: Growth of human tumour cells in established cultures. Methods Cancer Research 14, 243 (1978).
14. Eischen, C.M., Schilling, J.D., Lynch, D.H., Krammer, P.H., Liebson, P.J.: Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 156, 2693 (1996).
15. Loughran, T.P.: Clonal diseases of large granular lymphocytes. Blood 82, 1 (1993).
16. Hart, D.N.J., Baker, B.W., Inglis, M.J., Nimmo, J.C., Starling, G.C., Deacon, E., Rowe, M., Beard, M.E.J.: Epstein-Ban viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood 78, 2116 (1992).
17. Mori, N., Yatabe, Y., Oka, K., Kinoshita, T., Kobayashi, T., Ono, T., Asai, J.: Expression of perform in nasal lymphoma. Additional evidence of its natural killer cells derivation. Am J Pathol 149, 699 (1996).
18. Loughran, T.P.: personal communication (manuscript Brit J Haematol in print 1997).
19. Rethy, L.A., Horvath, J.C., Sinkovics, J.G., Uckan, D., Steele, A., Horvath, E., Horak, A., Good, R.A.: Subversion of host immunity by human melanoma cells. I. FasL counterattack on lymphocytes. Proc Am Assoc Cancer Res 38, 122 Abstract #812 (1997).
20. O'Connell, J., O'Sullivan, G.C., Collins, J.K., Shanahan, F.: The Fas counterattack: Fas-mediated T cell killing by colon carcinoma cells expressing Fas ligand. J Exp Med 184, 1075 (1996).
21. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornard, T., Fontana, A., Lienard, D., Cerottini, J-C., Tschopp, J.: Melanoma cell expression of Fas (APO-1/CD9S) ligand: implications for tumour immune escape. Science 274, 1363 (1996).
22. Saas, P., Walker, P.R., Hahne, M., Quiquerez, A-L., Schnuriger, V., Perrin, G., French, L., Van Meir, E.G., deTribolet, N., Tschopp, J., Dietrich, P-Y.: Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99, 1173 (1997).
23. Strand, S., Hofmann, W.J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S.M., Stremmel, W., Krammer, P.H., Galle, P.R.: Lymphocyte apoptosis induced by CD9S (APO-1/Fas) ligand-expressing tumour cells: a mechanism of immune evasion? Nature Med 2, 1361 (1996).
24. Niehans, G.A., Brunner, T., Frizelle, S.P., Liston, J.C., Salerno, C.T., Knapp, D.J., Green, D.R., Kratzke, R.A.: Human lung carcinomas express Fas ligand. Cancer Res 57, 1007 (1997).
25. Savary, C.A., Ju, D.: Induction of apoptosis in lymphocytes by breast carcinoma cells. Proceedings & Abstracts 17th Annual San Antonio Breast Cancer Symposium, 1994.
26. Gimmi, C.D., Morrison, B.W., Mainprice, B.A., Gribben, J.G., Boussiotis, V.A., Freeman, G.J., Park, S.Y.L., Watanabe, M., Gong, J.L., Hayes, D.F., Kufe, D.W., Nadler, L.M.: Breast cancer-associated antigen DF3/MUC1 induces apoptosis of activated human T cells. Nature Med 2, 1367 (1996).
27. Sinkovics, J.G., Cabiness, J.R., Shullenberger, C.C.: Monitoring in vitro immune reactions to solid tumours. Front Rad Therapy Oncology 7, 141 (1972).
28. Kay, H.D., Sinkovics, J.G.: Project M30/gm 23: Self defensive mechanisms of tumour cells. Research report University Texas MD Anderson Hospital, Houston TX, 1976. pp. 562-564.
29. Sinkovics, J.G.: Cytotoxic lymphocytes. Annals Clin Lab Sci 16, 488 (1986).
30. Sinkovics, J.G., Campos, L.T., Loh, K.K., Cormia, F., Velasquez, W., Shullenberger, C.C.: Chemo-immunotherapy for three categories of solid tumours (sarcoma, melanoma, lymphoma): the problem of immunoresistant tumours. In Crispen, R.G. (ed.): Neoplasm Immunity: Mechanisms. The University Illinois, Chicago, 1976. pp. 193-212.
31. Sinkovics, J.G.: Programmed cell death (apoptosis): its virological and immunological connections. Acta Microbiol Hung 38, 321 (1991).
32. Sinkovics, J.G., Horvath, J.: Cytotoxic human lymphocytes: from in vitro testing (1970s) to immunotherapy (1990s). Acta Microbiol Hung 40, 165 (1993).
33. Sinkovics, J.G., Horvath, J.: Can virus therapy of human cancer be improved by apoptosis induction? Medical Hypotheses 44, 359 (1995).
34. Owen-Schaub, L.B., Radinsky, R., Kruzel, E., Berry, K., Yonehara, S.: Anti-Fas on nonhematopoietic tumours: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54, 1580 (1994).
35. Goillot, E., Combaret, V., Ladenstein, R., Baubet, D., Blay, J-Y., Philip, T., Favrot, M.C.: Tumour necrosis factor as an autocrine growth factor for neuroblastoma. Cancer Res 52, 3194 (1992).
36. Modrowski, D., Godet, D., Marie, P.J.: Involvement of interleukin 1 and tumour necrosis factor a as endogenous growth factors in human osteoblastic cells. Cytokine 7, 720 (1995).
37. Horvath, J.C., Horvath, E., Sinkovics, J.G., Horak, A., Pendleton, S.: Subversion of host defenses by human melanoma cells: anti-apoptotic events. Abstracts, Internat Soc Analytic Cytology, Sam Latt Conference Toronto, Canada, June 20 1997. p. 7.
38. Sinkovics, J.G., Horvath, J., Horak, A.: Counterattack on host lymphocytes and on apoptosis by human melanoma cells. 4th International Congress on Biological Response Modifiers. Abstract #1 San Antonio TX, March 13 1997. p. 74.
39. Takahashi, T., Tanaka, M., Ogasawara, J., Suda, T., Murokami, H., Nagata, S.: Swapping between Fas and granulocyte colony-stimulating factor receptor. J Biol Chemistry 271, 17555 (1996).
40. Safarians, S., Rivera, S.P., Sternblicht, M.D., Naeim, F., Barsky, S.H.: Ectopic G-CSF expression in human melanoma lines marks a transdominant pathway of tumour progression. Am J Pathol 150, 949 (1997).
41. Sinkovics, J.G.: The graft-versus-leukaemia (GvL) reaction: its early history, value in human bone marrow transplantation and recent developments concerning its mechanism and induction. In Proceedings 7th International Symposium on Autologous Bone Marrow & Blood Transplantation. The Cancer Treatment Research & Educational Institute, Arlington TX, 1995. pp. 233; 305-318.
42. Han, D., Pattin-Clemenceau, C., Imro, M.A., Scudeletti, M., Doucet, C., Puppo, F., Brouty-Boye, D., Vedreune, J., Sahraoui, Y., Brailly, H., Poggi, A., Jasmin, C., Azzarone, B., Indiveri, F.: IL-2 triggers a tumour progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL-2/INFa biotherapy. Oncogene 12, 1015 (1996).
43. Lu, C., Sheehan, C., Rak, J.W., Chambers, C.A., Hozumi, N., Kerbel, R.S.: Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced stage human melanoma cells. Clin Cancer Res 2, 1417 (1996).
44. Francis, G.M., Krohn, E.G., Woods, K.V., Buzaid, A.C., Grimm, E.A.: Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1. Melanoma Res 6, 191 (1996).
45. Möhler, T., Scheibenbogen, C., Häfele, J., Willhauck, M., Keilholz, U.: Regulation of interleukin-8 mRNA expression and protein secretion in a melanoma cell line by tumour necrosis factor-α and interferon-γ. Melanoma Res 6, 307 (1996).
46. VandenOord, J.J., Vandeghinste, N., DeLey, M., Wolf-Peeters, C.D.: Bcl-2 expression in human melanocytes and melanocytic tumours. Am J Pathol 145, 294 (1994).
47. Plattenberg, A., Ballaun, C., Pammer, J., Mildner, M., Strunk, D., Weninger, W., Tschachler, E.: Human melanocytes and melanoma cells constitutively express the Bcl-2 protooncogene in situ and in culture. Am J Pathol 146, 651 (1995).
48. Tron, V.A., Krajewski, S., Klein-Parker, H., Li, G., Ho, V.C., Reed, J.C.: Immunohistochemical analysis of Bcl 2 protein regulation in cutaneous melanoma. Am J Pathol 146, 643 (1995).
49. Reed, J.A., McNutt, N.S., Prieto, V.G., Albino, A.P.: Expression of transforming growth factor-β2 in malignant melanoma correlates with depth of tumour invasion. Am J Pathol 145, 97 (1994).
50. Weiss, J., Schwechheimer, K., Cavenee, W.K., Herlyn, M., Arden, K.C.: Mutation and expression of the p53 gene in malignant melanoma cell line. Internat J Cancer 54, 693 (1993).
51. Lassam, N.J., From, L., Kahn, H.J.: Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 15, 2235 (1993).
52. Florenes, V.A., Holm, R., Fodstado.: Accumulation of p53 protein in human malignant melanoma: relationship to clinical outcome. Melanoma Res 5, 183 (1995).
53. Chiarugi, V., Ruggiero, M.: Role of three cancer "master genes" p53, bcl-2 and c-myc on the apoptotic process. Tumouri 87, 205 (1996).
54. Albino, A.P., Reed, J.A., McNutt, N.S.: Molecular biology of cutaneous malignant melanoma. In DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds): Cancer: Principles & Practice of Oncology 5th edition. Lippincott-Raven Philadelphia, 1997. pp. 1935-1946.
55. Oltvai, Z., Korsmeyer, S.J.: Checkpoints of dueling dimers foil death wishes. Cell 79, 189 (1992).
56. Friedlander, R.M., Gagliardini, V., Rotello, R.J., Yuan, J.: Functional role of interleukin 1β (IL-1β) in IL-1β-converting enzyme-mediated apoptosis. J Exp Med 184, 717 (1996).
57. Beg, A.A., Baltimore, D.: An essential role for NFκB in preventing TNFα-induced cell death. Science 274, 782 (1996).
58. VanAntwerp, D.J., Martin, S.J., Kafri, T., Green, D.R., Verna, I.M.: Suppression of TNFα-induced apoptosis by NFKB. Science 274, 787 (1996).
59. Gilmore, T.D., Koldood, M., Piffat, K.A., White, D.W.: Rel/NFκB/IκB proteins and cancer. Oncogene 13, 1367 (1996).
60. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S.C., Huvos, Ab, Healey, J.H.: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53, 16 (1993).
61. Ciotti, P., Imro, A., Scudeletti, M., Rainero, M.L., Defferrari, R., Ghiorzo, P., Indiveri, F., Bianchi-Scarra, G.: MlI-P a GM-CSF-producing human melanoma cell line. Melanoma Res 6, 203 (1996).
62. Herbst, R.A., Weiss, J., Ehnis, A., Cavenee, W.K., Arden, K.C.: Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res 54 3111 (1994).
63. Lu, C., Kerber, R.S.: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120, 1281 (1993).
64. Azzarone, B., Pottin-Clemenceau, C., Krief, P., Rubinstein, E., Jasmin, C., Scudeletti, M., Indiveri, F.: Are interleukin-2 and interleukin-15 tumour promoting factors for human non-hematopoietic cells? Europ Cytokine Netw 7, 27 (1996).